spacer
home > ebr > winter 2003 > understanding drug-kinase interactions with surface plasmon resonance (spr)
PUBLICATIONS
European Biopharmaceutical Review

Understanding Drug-Kinase Interactions with Surface Plasmon Resonance (SPR)

Protein kinases (PKs) represent one of the largest known superfamilies of human proteins. A recent report identified 510 candidate PK genes on the basis of sequence homology (1). PKs play critical roles in almost all signal transduction pathways, such as post-receptor cascades (2). Upstream signalling events are relayed by the action of PKs, usually via their phosphorylation of key serine, threonine or tyrosine residues on target proteins, using ATP or GTP as phosphate donors (3). These functions are carried out by a 250 amino acid catalytic domain, which is conserved among and used to identify members of the PK superfamily (4). This domain consists of an N-terminal lobe that binds and orientates the ATP/GTP, and a larger C-terminal lobe, which binds to the target protein and catalyses the transfer of phosphate.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Robert Karlsson, Director of Biochemistry and Chemistry at Biacore AB

Robert Karlsson joined Biacore in 1986 as one of the first five scientists in the company. In Biacore he has held several positions in both R&D and marketing. Mr Karlsson is currently Director of the Biochemistry and Chemistry Department of Biacore R&D at Biacore AB, with responsibility for leading both operational activities and the strategic development in these disciplines. Mr Karlsson has over 25 years' experience in the pharmaceutical and biotech industry. He has published around 30 papers on different aspects of Biacore analysis including methodology papers on mapping, kinetics, thermodynamics and concentration analysis, as well as application oriented papers on drug screening and ADME assays.

spacer
Robert Karlsson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI expert forecasts ‘huge growth in Middle East manufacturing with Europe a medium-term target’

CPhI Middle East & Africa (CPhI MEA) expert Madhukar Tanna, Chief Executive Officer of Pharmax, a United Arab Emirates (UAE) based branded generic manufacturer, says favourable conditions in the UAE are resulting in a boom of pharmaceutical manufacturing throughout the region. Government incentive schemes to increase domestic production, coupled with a brand friendly environment and rising healthcare needs is fuelling surging demand – with many new companies and plants launching in the last two years alone.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement